References
- Retinal Biologics Market Expected to Increase at a 11.1% CAGR Through 2028 – Future Market Insights (2019). https://www.prnewswire.co.uk/news-releases/retinal-biologics-market-expected-to-increase-at-a-11-1-cagr-through-2028-future-market-insights-829825263.html.
- Controlled Release Drug Delivery Market Worth $90.18 Billion by 2025: Grand View Research, Inc. (2019). https://www.prnewswire.co.uk/news-releases/controlled-release-drug-delivery-market-worth-90-18-billion-by-2025-grand-view-research-inc–890736516.html
- ResearchAndMarkets.com ( Ed.). Drug Delivery in Central Nervous System (CNS) Diseases: 2019 Technologies, Markets & Companies – Forecast to 2028 (2019). https://www.businesswire.com/news/home/20190204005293/en/Drug-Delivery-Central-Nervous-System-CNS-Diseases.
- Ocular Therapeutix™ prices $37.5 million subordinated convertible debt financing (2019). http://investors.ocutx.com/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2388532
- Ocular Therapeutix™ announces dosing of first patient in otx-tki (tyrosine kinase inhibitor implant) Phase 1 clinical trial for the treatment of wet age-related macular degeneration (AMD) (2019). http://investors.ocutx.com/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2388136
- Sosei Heptares announces Medicxi to invest up to €40 million in new collaboration based on its Orexin agonist program (2019). https://soseiheptares.com/news/486/129/Sosei-Heptares-announces-Medicxi-to-invest-up-to-40-million-in-new-collaboration-based-on-its-orexin-agonist-program.html
- Moberg Pharma and Bayer sign exclusive license agreement for mo B-015 in Europe(2019). http://www.mobergpharma.com/press-releases/2019-02-11/moberg-pharma-and-bayer-sign-exclusive-license-agreement-mob-015-europe
- Ompi and SiO2 Medical Products (SMP) sign a collaboration agreement to provide SMP's containers in EZ-fill® configuration (2019). https://www.prnewswire.com/news-releases/ompi-and-sio2-medical-products-smp-sign-a-collaboration-agreement-to-provide-smps-containers-in-ez-fill-configuration-300785310.html
- Biocorp and AgaMatrix Announce a Strategic Partnership Based on the Insulin Dose Capture Pen Cap Mallya® and AgaMatrix's Blood Glucose Monitoring Solutions (2019). https://www.businesswire.com/news/home/20190218005114/en/BIOCORP-AgaMatrix-Announce-Strategic-Partnership-Based-Insulin
- ARS Pharmaceuticals Announces FDA Fast Track Designation for ARS-1 Intranasal Epinephrine Spray (2019). https://ars-pharma.com/2019/02/19/ars-pharmaceuticals-announces-fda-fast-track-designation-for-ars-1-intranasal-epinephrine-spray/
- Xellia Pharmaceuticals Receives US FDA Approval for Premixed Vancomycin Injection (2019). https://www.xellia.com/media/press-releases-and-news-archive/xellia-pharmaceuticals-receives-us-fda-approval-for-premixed-vancomycin-injection
- t:slim X2 Insulin Pump First to Receive New ACE Pump Classification by FDA (2019). https://www.businesswire.com/news/home/20190214005947/en/tslim-X2-Insulin-Pump-Receive-New-ACE
- 2019/02 Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer (2019). https://www.foreseepharma.com/index.php?class=news-detaile&cate=64&id=310&lang=en
- Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 (2019). http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-doses-first-patients-phase-2a-trial-op0201
- Chen J , LuY , ChengYet al. Novel strategy of gene delivery system based on dendrimer loaded recombinant hirudine plasmid for thrombus targeting therapy. Mol. Pharm.16(4), 1648–1657 (2019).
- New Cell-Based Technology by Cytonus Aims to Revolutionize the Fight against Cancer and Inflammatory Diseases (2019). http://innovation.ucsd.edu/2019/02/06/new-cell-based-technology-by-cytonus-aims-to-revolutionize-the-fight-against-cancer-and-inflammatory-diseases/
- Service RF . Pills give patients a shot inside the stomach. Science363(6427), 571 (2019).
- Abramson A , Caffarel-SalvadorE , KhangMet al. An ingestible self-orienting system for oral delivery of macromolecules. Science363(6427), 611–615 (2019).